Want to see HK:3692 full AI Analyst Report?
3692 Stock Chart & Stats
HK$39.76
HK$0.26(1.60%)
At close: 4:00 PM EST
HK$39.76
HK$0.26(1.60%)
Day’s Range― - ―
52-Week RangeHK$28.06 - HK$44.22
Previous CloseN/A
Volume4.63M
Average Volume (3M)9.67M
Market Cap
HK$179.62B
Enterprise ValueHK$151.91B
Total Cash (Recent Filing)HK$31.58B
Total Debt (Recent Filing)HK$105.14M
Price to Earnings (P/E)27.5
Beta0.52
Next Earnings
Aug 20, 2026EPS Estimate
0.57Next Dividend Ex-DateN/A
Dividend Yield0.97%
Share Statistics
EPS (TTM)0.93
Shares Outstanding6,064,150,000
10 Day Avg. Volume6,926,281
30 Day Avg. Volume9,666,344
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)5.48
Price to Sales (P/S)12.90
P/FCF Ratio31.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$46.90Price Target Upside17.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)0.98
Revenue Forecast (FY)HK$16.93B
Bulls Say, Bears Say
Bulls Say
High Profitability / MarginsSustained very high gross and healthy net margins indicate durable pricing power for branded drugs and efficient manufacturing. That margin profile supports reinvestment in R&D, funds marketing for new launches, and creates a durable earnings buffer versus cost shocks over a multi‑quarter horizon.
Conservative Balance SheetExtremely low leverage provides long-term financial flexibility to fund R&D, M&A or withstand procurement cycles without liquidity strain. A strong equity base reduces refinancing risk and supports consistent investment in commercialization and clinical programs over the next several quarters.
Improving Revenue Growth And Cash GenerationRe-accelerating top-line alongside operating cash flow materially ahead of net income shows earnings quality and conversion. Reliable cash generation supports sustained product launches, working capital needs, and potential reinvestment in higher-value therapeutic R&D over the medium term.
Bears Say
Margin & Cash Conversion VolatilityHistoric swings in operating cash conversion and margins reduce predictability of free cash flow and complicate budgeting for R&D and commercialization. Such volatility can impair long-term planning, increase funding needs in down years, and raises forecasting risk for investors and management alike.
Historical Capital Structure ShiftsPast episodes of materially higher leverage signal management has altered financing posture historically, which could recur under stress or for opportunistic deals. This inconsistency may increase refinancing or covenant risk and indicates capital allocation that has varied across cycles.
Concentration In Mainland China MarketHeavy reliance on the China market concentrates exposure to domestic regulatory, procurement and reimbursement policy changes. Structural shifts in tendering, hospital procurement rules, or reimbursement coverage can materially affect multi‑quarter revenue streams and adoption of newly launched drugs.
Hansoh Pharmaceutical Group Company Limited News
3692 FAQ
What was Hansoh Pharmaceutical Group Company Limited’s price range in the past 12 months?
Hansoh Pharmaceutical Group Company Limited lowest stock price was HK$28.06 and its highest was HK$44.22 in the past 12 months.
What is Hansoh Pharmaceutical Group Company Limited’s market cap?
Hansoh Pharmaceutical Group Company Limited’s market cap is HK$179.62B.
When is Hansoh Pharmaceutical Group Company Limited’s upcoming earnings report date?
Hansoh Pharmaceutical Group Company Limited’s upcoming earnings report date is Aug 20, 2026 which is in 50 days.
How were Hansoh Pharmaceutical Group Company Limited’s earnings last quarter?
Hansoh Pharmaceutical Group Company Limited released its earnings results on Mar 29, 2026. The company reported HK$0.462 earnings per share for the quarter, beating the consensus estimate of HK$0.393 by HK$0.069.
Is Hansoh Pharmaceutical Group Company Limited overvalued?
According to Wall Street analysts Hansoh Pharmaceutical Group Company Limited’s price is currently Undervalued.
Does Hansoh Pharmaceutical Group Company Limited pay dividends?
Hansoh Pharmaceutical Group Company Limited pays a Quarterly dividend of HK$0.2 which represents an annual dividend yield of 0.97%. See more information on Hansoh Pharmaceutical Group Company Limited dividends here
What is Hansoh Pharmaceutical Group Company Limited’s EPS estimate?
Hansoh Pharmaceutical Group Company Limited’s EPS estimate is 0.57.
How many shares outstanding does Hansoh Pharmaceutical Group Company Limited have?
Hansoh Pharmaceutical Group Company Limited has 6,064,150,000 shares outstanding.
What happened to Hansoh Pharmaceutical Group Company Limited’s price movement after its last earnings report?
Hansoh Pharmaceutical Group Company Limited reported an EPS of HK$0.462 in its last earnings report, beating expectations of HK$0.393. Following the earnings report the stock price went down -0.648%.
Which hedge fund is a major shareholder of Hansoh Pharmaceutical Group Company Limited?
Currently, no hedge funds are holding shares in HK:3692
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hansoh Pharmaceutical Group Company Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$46.90 (17.95% Upside)
HK$46.90 (17.95% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.01%
12-Months-Change
Fundamentals
Return on Equity
16.71%
Trailing 12-Months
Asset Growth
31.91%
Trailing 12-Months
Company Description
Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
3692 Stock 12 Month Forecast
Average Price Target
HK$46.90
▲(17.95% Upside)
Technical Analysis
HUTCHMED (China)
―
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
China Resources Pharmaceutical Group Ltd.
―
Options Prices
Currently, No data available
---